In any case, our findings imply that human PLD4 polymorphism and deficiency may have diverse phenotypic presentations ranging from hemophagocytic lymphohistiocytosis to lupus, and that all may be treatable by blockade of TLR9. The gene discussed is TLR9; the disease is systemic lupus erythematosus.